Crosstalk between bone niche and immune system: Osteoimmunology signaling as a potential target for cancer treatment

Cancer Treatment Reviews

Volumn 41, Issue 2, 2015, Pages 61-68

  Criscitiello, Carmen ^a   Viale, Giulia ^a   Gelao, Lucia ^a   Esposito, Angela ^a   De Laurentiis, Michele ^b   De Placido, Sabino ^c   Santangelo, Michele ^c   Goldhirsch, Aron ^a   Curigliano, Giuseppe ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Bone; Cancer; Immune system; Osteoimmunology; RANK

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BONE DENSITY CONSERVATION AGENT; CLODRONIC ACID; IBANDRONIC ACID; IMIDAZOLE DERIVATIVE; MONOCLONAL ANTIBODY; OSTEOPROTEGERIN; PAMIDRONIC ACID;

BONE; BONE TURNOVER; CANCER CELL; CANCER IMMUNOLOGY; CANCER PATIENT; CANCER THERAPY; DRUG SAFETY; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; MOLECULAR INTERACTION; MOLECULARLY TARGETED THERAPY; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOCYTE; OSTEOLYSIS; REVIEW; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE DISEASE; BONE NEOPLASMS; BONE REMODELING; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; SECONDARY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; BONE NEOPLASMS; BONE REMODELING; BONE RESORPTION; CLODRONIC ACID; DIPHOSPHONATES; HUMANS; IMIDAZOLES; IMMUNE SYSTEM; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84921811174     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.12.001     Document Type: Review

References (99)

1. Terpos E., Dimopoulos M.A. Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications. Cancer Immunol Immunother 2011, 60:305-317.
2. Boyce B.F., Xing L. The RANKL/RANK/OPG pathway. Curr Osteoporosis Rep 2007, 5:98-104.
3. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007, 7:292-304.
4. Caetano-Lopes J., Canhao H., Fonseca J.E. Osteoimmunology - the hidden immune regulation of bone. Autoimmun Rev 2009, 8:250-255.
5. Theill L.E., Boyle W.J., Penninger J.M. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 2002, 20:795-823.
6. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001, 142:5050-5055.
7. Trouvin A.P., Goeb V. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clin Interv Aging 2010, 5:345-354.
8. Dougall W.C., Glaccum M., Charrier K., Rohrbach K., Brasel K., De Smedt T., et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999, 13:2412-2424.
9. Lorenzo J. Interactions between immune and bone cells: new insights with many remaining questions. J Clin Investig 2000, 106:749-752.
10. Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M., et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997, 272:25190-25194.
11. Walsh M.C., Choi Y. Biology of the TRANCE axis. Cytokine Growth Factor Rev 2003, 14:251-263.
12. Lee N.K., Choi Y.G., Baik J.Y., Han S.Y., Jeong D.W., Bae Y.S., et al. A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood 2005, 106:852-859.
13. Baud'huin M., Duplomb L., Ruiz Velasco C., Fortun Y., Heymann D., Padrines M. Key roles of the OPG-RANK-RANKL system in bone oncology. Expert Rev Anticancer Ther 2007, 7:221-232.
14. Cheng M.L., Fong L. Effects of RANKL-targeted therapy in immunity and cancer. Front Oncol 2014, 3:329.
15. Akiyama T., Shimo Y., Yanai H., Qin J., Ohshima D., Maruyama Y., et al. The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. Immunity 2008, 29:423-437.
16. Hon H., Rucker E.B., Hennighausen L., Jacob J. Bcl-xL is critical for dendritic cell survival in vivo. J Immunol 2004, 173:4425-4432.
17. Cremer I., Dieu-Nosjean M.C., Marechal S., Dezutter-Dambuyant C., Goddard S., Adams D., et al. Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. Blood 2002, 100:3646-3655.
18. Seshasayee D., Wang H., Lee W.P., Gribling P., Ross J., Van Bruggen N., et al. A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response. J Biol Chem 2004, 279:30202-30209.
19. Yun T.J., Tallquist M.D., Aicher A., Rafferty K.L., Marshall A.J., Moon J.J., et al. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. Journal Immunol 2001, 166:1482-1491.
20. Chino T., Draves K.E., Clark E.A. Regulation of dendritic cell survival and cytokine production by osteoprotegerin. J Leukoc Biol 2009, 86:933-940.
21. Sobacchi C., Frattini A., Guerrini M.M., Abinun M., Pangrazio A., Susani L., et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet 2007, 39:960-962.
22. Sato K., Suematsu A., Okamoto K., Yamaguchi A., Morishita Y., Kadono Y., et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006, 203:2673-2682.
23. Kotake S., Udagawa N., Takahashi N., Matsuzaki K., Itoh K., Ishiyama S., et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Investig 1999, 103:1345-1352.
24. Danks L., Takayanagi H. Immunology and bone. J Biochem 2013, 154:29-39.
25. Miossec P., Kolls J.K. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discovery 2012, 11:763-776.
26. Arai F., Hirao A., Ohmura M., Sato H., Matsuoka S., Takubo K., et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 2004, 118:149-161.
27. Ding L., Saunders T.L., Enikolopov G., Morrison S.J. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature 2012, 481:457-462.
28. Li H., Lu Y., Qian J., Zheng Y., Zhang M., Bi E., et al. Human osteoclasts are inducible immunosuppressive cells in response to T cell-derived IFN-gamma and CD40 ligand in vitro. J Bone Miner Res 2014.
29. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
30. Bidwell B.N., Slaney C.Y., Withana N.P., Forster S., Cao Y., Loi S., et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med 2012, 18:1224-1231.
31. Roodman G.D., Dougall W.C. RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev 2008, 34:92-101.
32. Jones D.H., Nakashima T., Sanchez O.H., Kozieradzki I., Komarova S.V., Sarosi I., et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006, 440:692-696.
33. Morony S., Capparelli C., Sarosi I., Lacey D.L., Dunstan C.R., Kostenuik P.J. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001, 61:4432-4436.
34. Colucci S., Brunetti G., Rizzi R., Zonno A., Mori G., Colaianni G., et al. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood 2004, 104:3722-3730.
35. Roato I., Gorassini E., Buffoni L., Lyberis P., Ruffini E., Bonello L., et al. Spontaneous osteoclastogenesis is a predictive factor for bone metastases from non-small cell lung cancer. Lung Cancer 2008, 61:109-116.
36. Zhang K., Kim S., Cremasco V., Hirbe A.C., Collins L., Piwnica-Worms D., et al. CD8+ T cells regulate bone tumor burden independent of osteoclast resorption. Cancer Res 2011, 71:4799-4808.
37. Roato I., Caldo D., Godio L., D'Amico L., Giannoni P., Morello E., et al. Bone invading NSCLC cells produce IL-7: mice model and human histologic data. BMC Cancer 2010, 10:12.
38. Wrzesinski S.H., Wan Y.Y., Flavell R.A. Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin Cancer Res 2007, 13:5262-5270.
39. Gul N., Babes L., Siegmund K., Korthouwer R., Bogels M., Braster R., et al. Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J Clin Investig 2014, 124:812-823.
40. Milone F., Pivonello C., Cariati F., Sarnataro M., Ramundo V., Marotta V., et al. Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases. Biomarkers 2013, 18:121-125.
41. Todenhofer T., Hennenlotter J., Leidenberger P., Wald A., Hohneder A., Kuhs U., et al. Serum receptor activator of nuclear factor kappaB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy. BJU Int 2014, 113:152-159.
42. Di Francesco S., Castellan P., Manco R., Tenaglia R.L. Reciprocal cross-talk between Prostaglandin E2 and bone in prostate cancer: a current review. Cent Eur J Urol 2011, 64:201-204.
43. Weilbaecher K.N., Guise T.A., McCauley L.K. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011, 11:411-425.
44. Kyle R.A., Gertz M.A., Witzig T.E., Lust J.A., Lacy M.Q., Dispenzieri A., et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003, 78:21-33.
45. Russell R.G. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci 2006, 1068:367-401.
46. Clezardin P. Potential anticancer properties of bisphosphonates: insights from preclinical studies. Anti-Cancer Agents Med Chem 2012, 12:102-113.
47. Santini D., Martini F., Fratto M.E., Galluzzo S., Vincenzi B., Agrati C., et al. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother 2009, 58:31-38.
48. Thompson K., Roelofs A.J., Jauhiainen M., Monkkonen H., Monkkonen J., Rogers M.J. Activation of gammadelta T cells by bisphosphonates. Adv Exp Med Biol 2010, 658:11-20.
49. Paterson A.H., Powles T.J., Kanis J.A., McCloskey E., Hanson J., Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993, 11:59-65.
50. McCloskey E.V., Dunn J.A., Kanis J.A., MacLennan I.C., Drayson M.T. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 2001, 113:1035-1043.
51. Dearnaley D.P., Mason M.D., Parmar M.K., Sanders K., Sydes M.R. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 2009, 10:872-876.
52. Anagha P.P., Sen S. The efficacy of bisphosphonates in preventing aromatase inhibitor induced bone loss for postmenopausal women with early breast cancer: a systematic review and meta-analysis. J Oncol 2014, 2014:625060.
53. Palmieri C., Fullarton J.R., Brown J. Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis. Clin Cancer Res 2013, 19:6863-6872.
54. Fournier P.G., Stresing V., Ebetino F.H., Clezardin P. How do bisphosphonates inhibit bone metastasis in vivo?. Neoplasia 2010, 12:571-578.
55. Welton J.L., Morgan M.P., Marti S., Stone M.D., Moser B., Sewell A.K., et al. Monocytes and gammadelta T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial. J Bone Miner Res 2013, 28:464-471.
56. Ibrahim T., Liverani C., Mercatali L., Sacanna E., Zanoni M., Fabbri F., et al. Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines. Int J Oncol 2013, 42:1263-1270.
57. Cirak Y., Varol U., Atmaca H., Kisim A., Sezgin C., Karabulut B., et al. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A. BJU Int 2012, 110:E1147-54.
58. Dos Santos M.P., de Farias C.B., Roesler R., Brunetto A.L., Abujamra A.L. In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: a paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma. Oncol Rep 2014, 31:955-968.
59. Banys M., Solomayer E.F., Gebauer G., Janni W., Krawczyk N., Lueck H.J., et al. Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial. BMC Cancer 2013, 13:480.
60. Solomayer E.F., Gebauer G., Hirnle P., Janni W., Luck H.J., Becker S., et al. Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients. Ann Oncol 2012, 23:2271-2277.
61. Mystakidou K., Katsouda E., Parpa E., Kelekis A., Galanos A., Vlahos L. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 2005, 22:195-201.
62. Muinelo-Romay L., Garcia D., Alonso-Alconada L., Vieito M., Carmona M., Martinez N., et al. Zoledronic acid as an antimetastatic agent for different human tumor cell lines. Anticancer Res 2013, 33:5295-5300.
63. Valachis A., Polyzos N.P., Coleman R.E., Gnant M., Eidtmann H., Brufsky A.M., et al. Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist 2013, 18:353-361.
64. Gnant M. Role of bisphosphonates in postmenopausal women with breast cancer. Cancer Treat Rev 2014, 40:476-484.
65. Winter M.C., Coleman R.E. Bisphosphonates in the adjuvant treatment of breast cancer. Clin Oncol 2013, 25:135-145.
66. Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, et al. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev. 2010:CD003188.
67. Gonzalez-Suarez E. RANKL inhibition: a promising novel strategy for breast cancer treatment. Clin Transl Oncol 2011, 13:222-228.
68. Schramek D., Leibbrandt A., Sigl V., Kenner L., Pospisilik J.A., Lee H.J., et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010, 468:98-102.
69. Palafox M., Ferrer I., Pellegrini P., Vila S., Hernandez-Ortega S., Urruticoechea A., et al. RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. Cancer Res 2012, 72:2879-2888.
70. Goessl C., Katz L., Dougall W.C., Kostenuik P.J., Zoog H.B., Braun A., et al. The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction. Ann N Y Acad Sci 2012, 1263:29-40.
71. Peddi P., Lopez-Olivo M.A., Pratt G.F., Suarez-Almazor M.E. Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat Rev 2013, 39:97-104.
72. Lipton A., Fizazi K., Stopeck A.T., Henry D.H., Brown J.E., Yardley D.A., et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012, 48:3082-3092.
73. Rolfo C., Raez L.E., Russo A., Reguart N., Campelo R.G., Bronte G., et al. Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor. Expert Opin Biol Ther 2014, 14:15-26.
74. Smith M.R., Egerdie B., Hernandez Toriz N., Feldman R., Tammela T.L., Saad F., et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009, 361:745-755.
75. Ellis G.K., Bone H.G., Chlebowski R., Paul D., Spadafora S., Smith J., et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008, 26:4875-4882.
76. Xue F., Ma H., Stehman-Breen C., Haller C., Katz L., Wagman R.B., et al. Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia(R) (denosumab) for the treatment of postmenopausal osteoporosis. Pharmacoepidemiol Drug Saf 2013, 22:1107-1114.
77. Ferrari-Lacraz S., Ferrari S. Do RANKL inhibitors (denosumab) affect inflammation and immunity?. Osteoporosis Int 2011, 22:435-446.
78. Croucher P.I., Shipman C.M., Lippitt J., Perry M., Asosingh K., Hijzen A., et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001, 98:3534-3540.
79. Body J.J., Greipp P., Coleman R.E., Facon T., Geurs F., Fermand J.P., et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003, 97:887-892.
80. Holen I., Shipman C.M. Role of osteoprotegerin (OPG) in cancer. Clin Sci 2006, 110:279-291.
81. Holen I., Cross S.S., Neville-Webbe H.L., Cross N.A., Balasubramanian S.P., Croucher P.I., et al. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo - a role in tumour cell survival?. Breast Cancer Res Treat 2005, 92:207-215.
82. Mizutani Y., Matsubara H., Yamamoto K., Nan Li Y., Mikami K., Okihara K., et al. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma. Cancer 2004, 101:1794-1802.
83. Levidou G., Thymara I., Saetta A.A., Papanastasiou P., Pavlopoulos P., Sakellariou S., et al. TRAIL and osteoprotegerin (OPG) expression in bladder urothelial carcinoma: correlation with clinicopathological parameters and prognosis. Pathology 2013, 45:138-144.
84. Coleman R., de Boer R., Eidtmann H., Llombart A., Davidson N., Neven P., et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 2013, 24:398-405.
85. Loser K., Mehling A., Loeser S., Apelt J., Kuhn A., Grabbe S., et al. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med 2006, 12:1372-1379.
86. Calvi L.M., Adams G.B., Weibrecht K.W., Weber J.M., Olson D.P., Knight M.C., et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003, 425:841-846.
87. Becker T.C., Coley S.M., Wherry E.J., Ahmed R. Bone marrow is a preferred site for homeostatic proliferation of memory CD8 T cells. J Immunol 2005, 174:1269-1273.
88. Powles T., Paterson A., McCloskey E., Schein P., Scheffler B., Tidy A., et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006, 8:R13.
89. Diel I.J., Jaschke A., Solomayer E.F., Gollan C., Bastert G., Sohn C., et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 2008, 19:2007-2011.
90. Paterson A.H., Anderson S.J., Lembersky B.C., Fehrenbacher L., Falkson C.I., King K.M., et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol 2012, 13:734-742.
91. Saarto T., Vehmanen L., Virkkunen P., Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004, 43:650-656.
92. Rosen L.S., Gordon D., Kaminski M., Howell A., Belch A., Mackey J., et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001, 7:377-387.
93. Kohno N., Aogi K., Minami H., Nakamura S., Asaga T., Iino Y., et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005, 23:3314-3321.
94. Rosen L.S., Gordon D., Tchekmedyian N.S., Yanagihara R., Hirsh V., Krzakowski M., et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004, 100:2613-2621.
95. Hirsh V., Tchekmedyian N.S., Rosen L.S., Zheng M., Hei Y.J. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer 2004, 6:170-174.
96. Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., Lacombe L., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004, 96:879-882.
97. Berenson J.R., Lichtenstein A., Porter L., Dimopoulos M.A., Bordoni R., George S., et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996, 334:488-493.
98. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev. 2005:CD003474.
99. Devitt B., McLachlan S.A. Use of ibandronate in the prevention of skeletal events in metastatic breast cancer. Ther Clin Risk Manag 2008, 4:453-458.